Somewhat Positive News Coverage Somewhat Unlikely to Impact Kala Pharmaceuticals (KALA) Share Price

Media coverage about Kala Pharmaceuticals (NASDAQ:KALA) has trended somewhat positive on Monday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kala Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.5791180112068 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of research firms have recently weighed in on KALA. BidaskClub raised shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 16th. Wells Fargo & Co reissued an “outperform” rating and set a $19.00 target price (down from $24.00) on shares of Kala Pharmaceuticals in a research report on Thursday, January 25th. They noted that the move was a valuation call. Wedbush reissued an “outperform” rating and set a $46.00 target price on shares of Kala Pharmaceuticals in a research report on Friday, December 22nd. Finally, JPMorgan Chase & Co. set a $35.00 target price on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, November 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $35.80.

How to Become a New Pot Stock Millionaire

Kala Pharmaceuticals (NASDAQ KALA) traded down $0.19 during trading on Monday, hitting $17.33. 107,900 shares of the stock were exchanged, compared to its average volume of 407,403. Kala Pharmaceuticals has a 1 year low of $11.81 and a 1 year high of $26.75. The company has a market cap of $426.79 and a P/E ratio of -9.57. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14.

In other Kala Pharmaceuticals news, major shareholder Orbimed Advisors Llc purchased 170,338 shares of the company’s stock in a transaction that occurred on Wednesday, January 10th. The shares were bought at an average cost of $12.83 per share, for a total transaction of $2,185,436.54. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders have purchased a total of 1,108,150 shares of company stock worth $15,772,394 over the last 90 days.

COPYRIGHT VIOLATION WARNING: This article was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Insider Buying and Selling by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply